Jazz Pharmaceuticals Completes Acquisition of Chimerix

Jazz Pharmaceuticals ( (JAZZ) ) has provided an announcement.

On April 21, 2025, Jazz Pharmaceuticals announced the completion of its acquisition of Chimerix, Inc. for approximately $935 million. This acquisition enhances Jazz’s oncology pipeline with the addition of dordaviprone, a novel treatment under FDA Priority Review for H3 K27M-mutant diffuse glioma. The merger positions Jazz to potentially offer the first FDA-approved therapy for this condition, reflecting a significant commercial opportunity and reinforcing its commitment to addressing rare diseases with unmet needs.

Spark’s Take on JAZZ Stock

According to Spark, TipRanks’ AI Analyst, JAZZ is a Neutral.

Jazz Pharmaceuticals presents a mixed outlook. Strong financial performance and strategic acquisitions support a positive long-term view. However, current technical indicators suggest a challenging stock trend in the short term. Valuation appears favorable with a low P/E ratio, but the lack of dividends and potential revenue impacts from generic competition add caution. The earnings call’s positive sentiment and strategic initiatives, despite some challenges, contribute to a moderately positive score.

To see Spark’s full report on JAZZ stock, click here.

More about Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company headquartered in Dublin, Ireland, focusing on developing life-changing medicines for serious diseases with limited or no therapeutic options. The company has a diverse portfolio that includes leading therapies for sleep disorders, epilepsy, and a growing range of cancer treatments, driven by a patient-focused and science-driven approach.

YTD Price Performance: -16.95%

Average Trading Volume: 1,131,762

Technical Sentiment Signal: Strong Buy

Current Market Cap: $6.24B

See more insights into JAZZ stock on TipRanks’ Stock Analysis page.